Aurobindo Pharma reported consolidated revenue of ₹86.46 billion in Q3FY26, up 8.36% YoY, with net profit at ₹9.1 billion. Despite a one-time labour code charge of ₹653.3 million, the company maintained robust margins and announced a ₹660 million investment for a 26% stake in Garuda Renewables.
Aurobindo Pharma Limited has posted resilient financial results for the third quarter of FY26, reflecting strong operational momentum across geographies and strategic expansion initiatives. The company’s performance was driven by robust growth in Europe and stable US revenues, alongside continued progress in biologics and acquisitions.
Key Highlights
-
Revenue from operations stood at ₹86.46 billion, marking an 8.36% year-on-year increase
-
Net profit reached ₹9.1 billion, despite absorbing a one-time charge of ₹653.3 million due to new labour code implementation
-
EBITDA came in at ₹17.73 billion, with margins at 20.5%, supported by strong European growth (+27.4% YoY) and steady US sales
-
Nine-month FY26 revenue totaled ₹247.99 billion, reflecting consistent expansion across subsidiaries and acquisitions
-
Strategic investment of ₹660 million announced for a 26% equity stake in Garuda Renewables, reinforcing commitment to sustainable energy initiatives
-
Pipeline progress highlighted at CuraTeQ Biologics, strengthening long-term growth prospects
-
Operational resilience maintained despite lower transient product sales in the US market
The company’s forward-looking strategy, combining organic growth with acquisitions such as agreements for Lannett Company LLC and Khandelwal Laboratories’ formulations business, positions it strongly for sustained performance in the coming quarters.
Sources: InvestyWise, ScanX News, Aurobindo Pharma Investor Updates